AstraZeneca, Baili Launch Clinical Trial Collaboration for Lung Cancer Drug Combination

AstraZeneca (AZN) has entered into a clinical trial collaboration and supply agreement with Baili Biopharmaceutical and Baili's unit SystImmune to assess the combination of Baili's cancer drug SI-B001 and AstraZeneca's Tagrisso to treat non-small cell lung cancer, Baili said Friday.

The combination will be studied in a phase 2a study sponsored and conducted by Baili.

The financial terms of the collaboration weren't disclosed.